Skip to main content

MPM Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

49
Companies
$3.9B
Total invested
$90.3M
Avg. check
18
Industries
Biotechnology 17Therapeutics 10Health Care 9Medical 9Pharmaceutical 7Life Science 4+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 49
Photys Therapeutics
September 2022

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Biotechnology · Cambridge$75.0M Series A
Cerecor
August 2021

Cerecor discovers, develops and commercializes neuroscience drugs.

Biopharma · Baltimore$10.0M Post-IPO Debt
Orna Therapeutics
August 2022

Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.

Biotechnology · Cambridge$221.0M Series B
Rhythm Pharmaceuticals
July 2025

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Biotechnology · Boston$175.0M Post-IPO Equity
āshibio
June 2024

āshibio is a privately held biotechnology business exploring innovative therapies to treat bone and connective tissue ailments.

Biotechnology · Brisbane$40.0M Series A
ReNAgade Therapeutics
May 2023

ReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease.

Biotechnology · Cambridge$300.0M Series A
ITeos Therapeutics
May 2024

ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.

Biotechnology · Cambridge$120.0M Post-IPO Equity
Oncorus
April 2022

Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.

Biotechnology · Cambridge$20.0M Post-IPO Debt
TriNetX
April 2026

TriNetX is a health research network that connects drug discovery and development from pharmaceutical companies.

Analytics · Cambridge$200.0M Corporate Round
Crossbow Therapeutics
March 2026

Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.

Biotechnology · Cambridge$77.0M Series B
NextPoint Therapeutics
February 2024

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.

Biotechnology · Cambridge$42.5M Series B
Reunion Neuroscience
May 2025

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

Biotechnology · Toronto$68.9M Venture - Series Unknown
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
Deka Biosciences
December 2023

Early stage biotechnology company

Biotechnology · Germantown$29.9M Venture - Series Unknown
Arialys Therapeutics
September 2023

Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.

Health Care · La Jolla$58.0M Seed
SiO2 Materials Science
December 2021

SiO2 Materials Science is a plastic container designing company.

Manufacturing · Auburn$205.0M Debt Financing
CODA Biotherapeutics
December 2021

CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.

Biotechnology · South San Francisco$28.0M Venture - Series Unknown
AstronauTx
October 2023

AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.

Biotechnology · Reading$58.7M Series A
IOmx Therapeutics
October 2021

iOmx Therapeutics focuses on the development of cancer immunotherapy treatments.

Biopharma · Munich$75.4M Series B
Frontier Medicines
June 2024

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Biopharma · San Francisco$20.0M Series C
Werewolf Therapeutics
May 2022

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Biotechnology · Cambridge$50.0M Post Ipo Secondary

Where MPM Capital invests

Biotechnology17
Therapeutics10
Health Care9
Medical9
Pharmaceutical7
Life Science4

About MPM Capital's portfolio

How many companies has MPM Capital invested in?

MPM Capital has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does MPM Capital invest in?

MPM Capital's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 18 different industry categories.

What is MPM Capital's largest investment?

Among tracked funding rounds, ReNAgade Therapeutics received $300.0M in a Series A round. MPM Capital's total known invested capital is $3.9B.

What is the average investment size for MPM Capital?

MPM Capital's average investment size is $90.3M across its portfolio of 49 companies.

What are MPM Capital's most recent investments?

Recent MPM Capital portfolio additions include Photys Therapeutics, Cerecor, Orna Therapeutics, Rhythm Pharmaceuticals, āshibio. These companies were founded in 2020 or later.

Reach the founders behind these 49 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →